- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT04484909
NBTXR3 activado por radioterapia para el tratamiento del cáncer de páncreas localmente avanzado o resecable en el límite
Estudio de fase I de NBTXR3 activado por radioterapia para el adenocarcinoma ductal pancreático resecable localmente avanzado o limítrofe
To find the recommended dose of NBTXR3 that can be given in combination with radiation therapy to patients with pancreatic cancer. To learn if the dose NBTXR3 found in Part 1 can help to control the disease.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
PRIMARY OBJECTIVE:
• To determine the recommended phase II dose (RP2D) of NBTXR3 activated by radiotherapy in subjects with locally advanced or borderline-resectable pancreatic ductal adenocarcinoma.
SECONDARY OBJECTIVES:
- To evaluate the safety and feasibility of NBTXR3 intratumoral injection activated by radiotherapy in locally advanced or borderline-resectable pancreatic ductal adenocarcinoma
- To evaluate the anti-tumor response of NBTXR3 intratumoral injection activated by radiotherapy in subjects with locally advanced or borderline-resectable pancreatic ductal adenocarcinoma
- To evaluate time-to-event outcomes in subjects with locally advanced or borderline-resectable pancreatic ductal adenocarcinoma
EXPLORATORY OBJECTIVES:
- To evaluate the body kinetic profile of intratumorally injected NBTXR3.
- To evaluate time to event outcomes for subjects with clinical staging of locally advanced, unresectable disease.
- To evaluate resectability conversion rates.
- To evaluate surgical outcomes in subjects who undergo surgery after radiation therapy.
- To associate radiomic measurements with outcomes.
- To evaluate biomarkers of response in subjects treated with NBTXR3/RT.
OUTLINE: This is a dose-escalation study of NBTXR3.
Patients receive NBTXR3 intratumorally (IT) on day 1. Patients then undergo 15 fractions of intensity modulated radiation therapy (IMRT) between days 15-43 in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 1 month and then every 3 months for up to 1 year.
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Texas
-
Houston, Texas, Estados Unidos, 77030
- M D Anderson Cancer Center
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
1. Signed informed consent form (ICF) indicating that participant understands the purpose of, and procedures required for, the study and is willing to participate in the study 2. Age ≥ 18 years 3. Biopsy proven ductal adenocarcinoma of the pancreas,as defined by the following:
a. Borderline resectable pancreatic adenocarcinoma (BRPC) has no aortic involvement with at least ONE of the following features: i. Superior mesenteric vein (SMV) or Portal vein (PV) with a tumor interface of ≥ 180° OR short segment occlusion of SMV or PV amenable to reconstruction ii. Superior mesenteric artery (SMA) or celiac axis (CA) with a tumor interface of < 180° iii. Any degree of hepatic artery interface that is amenable to reconstruction b. Locally advanced pancreatic adenocarcinoma (LAPC) has at least ONE of the following features:
-
Signed informed consent form (ICF) indicating that participant understands the purpose of, and procedures required for, the study and is willing to participate in the study
-
Age ≥ 18 years
-
Biopsy proven ductal adenocarcinoma of the pancreas,as defined by the following:
a. Borderline resectable pancreatic adenocarcinoma (BRPC) has no aortic involvement with at least ONE of the following features: i. Superior mesenteric vein (SMV) or Portal vein (PV) with a tumor interface of ≥ 180° OR short segment occlusion of SMV or PV amenable to reconstruction ii. Superior mesenteric artery (SMA) or celiac axis (CA) with a tumor interface of < 180° iii. Any degree of hepatic artery interface that is amenable to reconstruction b. Locally advanced pancreatic adenocarcinoma (LAPC) has at least ONE of the following features: i. Occlusion of the SMV or PV that is not amenable to reconstruction ii. Tumor interface of the superior mesenteric artery or celiac axis ≥ 180° iii. Involvement of the hepatic artery that is not amenable to reconstruction iv. Involvement of the aorta
-
Has had a 4-month course (± 2-months) of chemotherapy for PDAC without radiographic evidence of distant metastatic disease. Following chemotherapy regimens are allowed:
- gemcitabine/nab-paclitaxel
- gemcitabine/capecitabine
- gemcitabine/cisplatin
- gemcitabine
- FOLFOX
- FOLFIRINOX
-
Amenable to undergo the endoscopic ultrasound guided injection of NBTXR3 as per investigator or treating physician.
-
Has a target lesion in the pancreas that is identifiable on cross sectional imaging by repeated measurements (via RECIST 1.1) at the same anatomical location
a. Nodal disease only is not allowed.
-
Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1
-
Laboratory Values at screening:
- Hemoglobin ≥ 8.0 g/dL
- Absolute Neutrophil Count (ANC) ≥ 1,500/mm3
- Platelet Count ≥ 100,000/mm3
- Creatinine ≤ 1.5 x upper limit of normal (ULN)
- Total Bilirubin ≤ 2.0 mg/dL
- AST / ALT ≤ 3.0 x upper limit of normal (ULN)
- Serum albumin ≥ 3.0 g/dL
-
Negative pregnancy test ≤ 7 days prior to NBTXR3 injection in all females of child-bearing potential
-
If participant has a history of prior duodenal or biliar plastic stent, it should be replaced with a metal stent ≥ 1 week prior to Study Day 1.
Exclusion Criteria:
-
Prior radiation therapy to the upper abdomen
-
Prior surgical resection of pancreatic tumor
-
Diagnosis other than pancreatic ductal adenocarcinoma. All other histologic types (i.e., adenosquamous, cystadenocarcinoma, etc.) are not eligible to participate on this study.
-
LAPC or BRPC with radiographic evidence of distant metastasis at screening.
-
Has received any approved or investigational anti-neoplastic agent other than the chemotherapies specified in this protocol (i.e. chemotherapies included in Inclusion #4)
-
Known uncontrolled (Grade ≥ 2) or active gastric or duodenal ulcer disease within 30 days of enrollment
-
Known contraindication to iodine-based or gadolinium-based IV contrast
-
Active malignancy, in addition to pancreatic cancer, with the exception of basal cell carcinoma of the skin definitively treated and relapse free within at least 1 year from diagnosis
-
Clinically significant cardiac arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, torsades de pointes, second or third degree atrioventricular heart block without a permanent pacemaker in place)
-
Class III or IV Congestive Heart Failure as defined by the New York Heart Association functional classification system <6 months prior to screening
-
Known active, uncontrolled (high viral load) HIV or hepatitis B or hepatitis C infection
a. Patients who have been vaccinated for hepatitis B and do not have a history of infection are eligible.
-
Female patients who are pregnant or breastfeeding
-
Women of child-bearing potential and their male partners who are unwilling or unable to use an acceptable method of birth control for the entire study period. Acceptable methods of contraception are those that, alone or in combination, result in a failure rate of < 1% per year when used consistently and correctly
-
Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (e.g., compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Treatment (NBTXR3, radiation therapy)
Patients receive NBTXR3 IT on day 1. Patients then undergo 15 fractions of radiation therapy between days 15-43 in the absence of disease progression or unacceptable toxicity. |
Undergo radiation therapy
Otros nombres:
Given IT
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Dosis recomendada de fase II (RP2D)
Periodo de tiempo: Hasta 1 año
|
Hasta 1 año
|
|
|
Dose-limiting toxicities
Periodo de tiempo: 4 weeks after last radiation dose
|
Any grade >= 3 adverse event related to NBTXR3 and/or radiation therapy. Any toxicity (grade >= 3) that is at least possibly related to study drug (NBTXR3) is a DLT. Adverse events will be scored based on National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE v 5.0). |
4 weeks after last radiation dose
|
|
Maximum tolerated dose (MTD)
Periodo de tiempo: Up to 1 year
|
MTD will be determined as the dose for which the isotonic estimate of the toxicity rate is closest to the target toxicity rate 30%. |
Up to 1 year
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Supervivencia libre de progresión (PFS)
Periodo de tiempo: Desde la inyección de NBTXR3 hasta la recurrencia local, la progresión local, la progresión a distancia o la muerte por cualquier causa, lo que ocurra primero, evaluado hasta 1 año
|
Desde la inyección de NBTXR3 hasta la recurrencia local, la progresión local, la progresión a distancia o la muerte por cualquier causa, lo que ocurra primero, evaluado hasta 1 año
|
|
|
Supervivencia global (SG)
Periodo de tiempo: Desde la inyección de NBTXR3 hasta la muerte por cualquier causa o EoS, lo que ocurra primero, evaluado hasta 1 año
|
Desde la inyección de NBTXR3 hasta la muerte por cualquier causa o EoS, lo que ocurra primero, evaluado hasta 1 año
|
|
|
Determination of the feasibility of NBTXR3 injection in pancreas
Periodo de tiempo: Up to 1 year
|
Feasibility refers to the ability to do intratumoral injection of NBTXR3. The outcome for each patient would be "feasible" or "not feasible." |
Up to 1 year
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Proporción de sujetos localmente avanzados que se someten a resección quirúrgica después de recibir NBTXR3/radioterapia (R3/RT)
Periodo de tiempo: Hasta 1 año
|
Hasta 1 año
|
|
|
Presence of hafnium
Periodo de tiempo: Up to 1 year
|
Will evaluation of the time-course dependent presence of hafnium in blood and urine following NBTXR3 intratumoral injection. |
Up to 1 year
|
|
Disease control rate
Periodo de tiempo: 6 months
|
Defined as the proportion of patients without progression 6 months post NBTXR3 injection. |
6 months
|
|
Resection status
Periodo de tiempo: Up to 1 year
|
Resection status as assessed macroscopically by surgeon R0- Macroscopically complete tumor removal with negative microscopic surgical margins, R1- Macroscopically complete tumor removal with positive microscopic margins (any or all), and R2- Macroscopically incomplete tumor removal with known or suspected residual gross disease. |
Up to 1 year
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Eugene J Koay, M.D. Anderson Cancer Center
Publicaciones y enlaces útiles
Enlaces Útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 2019-1001
- 2019-1001 (Otro identificador: M D Anderson Cancer Center)
- NCI-2020-03731 (Identificador de registro: CTRP (Clinical Trial Reporting Program))
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .